Latest Derivatives News

Almonty Industries reported significant losses in Q2 2025 as it advances the Sangdong tungsten mine in South Korea and completes a US$90 million Nasdaq IPO to fund growth projects.

Centuria Office REIT delivered FY25 results in line with guidance, marking a modest portfolio valuation gain and maintaining strong liquidity. The outlook for FY26 remains positive amid constrained office supply and rising rents.

Laramide Resources has made significant progress in advancing its uranium projects across the US, Australia, and Kazakhstan, highlighted by key permitting milestones under the US FAST-41 framework and a successful $12 million private placement to fund development.

Robex Resources Inc reported a substantial net loss for the first half of 2025, reflecting operational challenges and legal settlements, while advancing financing and construction of its key Kiniéro gold project in Guinea.

Suncorp Group reports a robust $1.82 billion net profit after tax for FY25, boosted by strategic divestments and strong insurance operations. The company announces a $400 million share buy-back as it sharpens focus on general insurance.

Talga Group has launched Talnode-R, a recycled graphite anode product derived from lithium-ion battery waste, aiming to transform battery supply chains with sustainable, modular production.

OD6 Metals has successfully produced high-quality rare earth products from its Splinter Rock project, positioning itself for premium market payability and strategic global partnerships.

EBR Systems has secured FDA approval for its pioneering leadless WiSE CRT System and obtained key Medicare reimbursement endorsements, setting the stage for its commercial rollout. The company also completed a significant capital raise to support its market expansion.

Insurance Australia Group Limited (IAG) has announced a quarterly distribution of AUD 1.4715 per security for its Capital Notes 3, reflecting a 5.9% annualised yield with partial franking.

Commonwealth Bank of Australia reported an 8% rise in net profit to $10.1 billion for FY25, supported by steady lending growth and a 5% revenue increase. The bank declared a fully franked final dividend of 260 cents per share, underscoring its robust capital position and ongoing technology modernization.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

Australian Gold and Copper Ltd reports strong flotation and leaching test results from its Achilles deposit, marking a key step toward a maiden Mineral Resource Estimate.